<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Vanda Pharmaceuticals Inc. | Company News & Executive Profiles - VNDA | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/vanda+pharmaceuticals+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Vanda Pharmaceuticals Inc.]]></description>
	<s:counts start="0" returned="10" found="18" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Titan Pharma Stock Remains Primed to Spike]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F170814-titan-pharma-stock-remains-primed-to-spike%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[VFC submits:  Titan Pharmaceuticals (TTNP.PK) was mentioned in a weekend article by the Washington Post that highlighted the CEO of Vanda Pharmaceuticals, Mihael Polymeropoulos, and Fanapt - Vanda's recently approved drug to treat schizophrenia of which Titan will reap up to 10% in royalties.While Novartis NVS emerged as Vanda's...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 03 Nov 2009 05:51:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/vfc%2527s+stock+house.html"><![CDATA[VFC's Stock House]]></category>
		<category domain="http://resources.bnet.com/topic/vanda+pharmaceuticals+inc..html"><![CDATA[Vanda Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VNDA</category>
		<category domain="tickers">VNDA</category>
	</item>
	<item>
		<title><![CDATA[Vanda Headed Higher on Novartis Deal]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F166229-vanda-headed-higher-on-novartis-deal%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[VFC submits:  Shares of Vanda Pharmaceuticals VNDA are set to trade to the upside on Tuesday after news was released on Monday evening detailing a licensing agreement with Novartis NVS for Fanapt that could be worth as much as $465 million. VNDA traded higher by 20% during the after...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 13 Oct 2009 06:43:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/vfc%2527s+stock+house.html"><![CDATA[VFC's Stock House]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/vanda+pharmaceuticals+inc..html"><![CDATA[Vanda Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VNDA</category>
		<category domain="tickers">NVS,VNDA</category>
	</item>
	<item>
		<title><![CDATA[The Worst Is Way Behind Titan Pharma]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F164444-the-worst-is-way-behind-titan-pharma%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[VFC submits:  [Update below] I've discussed Titan Pharmaceuticals (TTNP.PK) in great depth here over the past eight months or so, but a rundown of where I think this stock could go - based on the potential of Fanapt sales and Titan's 8-10% royalty rate - is as follows: by...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 02 Oct 2009 01:01:40 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/vfc%2527s+stock+house.html"><![CDATA[VFC's Stock House]]></category>
		<category domain="http://resources.bnet.com/topic/vanda+pharmaceuticals+inc..html"><![CDATA[Vanda Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VNDA</category>
		<category domain="tickers">VNDA</category>
	</item>
	<item>
		<title><![CDATA[Titan Pharma Investors' Wait Will Be Well Worth It]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F164109-titan-pharma-investors-wait-will-be-well-worth-it%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[VFC submits:  Shares of Titan Pharmaceuticals (TTNP.PK) continue to trade in a somewhat flat trading range as investors eagerly await the anticipated fourth quarter launch of Fanapt - a schizophrenia drug produced by Vanda Pharmaceuticals VNDA - of which Titan will receive between 8-10% in royalties. It's been long...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 30 Sep 2009 07:49:39 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/vfc%2527s+stock+house.html"><![CDATA[VFC's Stock House]]></category>
		<category domain="http://resources.bnet.com/topic/vanda+pharmaceuticals+inc..html"><![CDATA[Vanda Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VNDA</category>
		<category domain="tickers">VNDA</category>
	</item>
	<item>
		<title><![CDATA[Vanda Pharmaceuticals: Heavily Undervalued]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F147609-vanda-pharmaceuticals-heavily-undervalued%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Vanda Pharmaceuticals VNDA is making a stunning come back this year as FDA finally approved its schizophrenia drug Fanapt. But the story is far from over, and there is every reason to believe VNDA is still heavily undervalued and has huge upside potential. This is a potential giant market for...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 08 Jul 2009 04:32:55 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/penn+bioinvestor.html"><![CDATA[Penn Bioinvestor]]></category>
		<category domain="http://resources.bnet.com/topic/vanda+pharmaceuticals+inc..html"><![CDATA[Vanda Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VNDA</category>
		<category domain="tickers">VNDA</category>
	</item>
	<item>
		<title><![CDATA[Vanda Pharmaceuticals Comes Back from the Dead]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F146540-vanda-pharmaceuticals-comes-back-from-the-dead%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  I wrote last summer about Vanda Pharmaceuticals VNDA and their difficulty getting a new antipsychotic Fanapt iloperidone through the FDA. At the time, they'd received one of those wonderful requests for more information from the agency, of the kind that spread cheer whenever they appear. I...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 01 Jul 2009 01:32:34 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/vanda+pharmaceuticals+inc..html"><![CDATA[Vanda Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VNDA</category>
		<category domain="tickers">VNDA</category>
	</item>
	<item>
		<title><![CDATA[Competitive Technologies, Aethlon Medical: Pain Relief Without the Pills]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F142558-competitive-technologies-aethlon-medical-pain-relief-without-the-pills%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Danny Furman submits: I failed chemistry in college. My ego says it was because I didn't apply myself. Still I feel grossly inept when it comes to analyzing biotech stocks. I bought Vanda Pharmaceuticals VNDA near $1 because of their strong cash position, then sold at $1.23 to get my...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 11 Jun 2009 12:47:48 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/danny+furman.html"><![CDATA[Danny Furman]]></category>
		<category domain="http://resources.bnet.com/topic/competitive+technologies+inc..html"><![CDATA[Competitive Technologies Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/vanda+pharmaceuticals+inc..html"><![CDATA[Vanda Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CTT</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VNDA</category>
		<category domain="tickers">CTT,VNDA</category>
	</item>
	<item>
		<title><![CDATA[SAC Capital Discloses Vanda Pharmaceuticals Stake]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F142589-sac-capital-discloses-vanda-pharmaceuticals-stake%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Market Folly submits: In a 13G filed recently with the SEC, hedge fund SAC Capital has disclosed an 8.6% ownership stake in Vanda Pharmaceuticals VNDA. SAC now owns 2,279,423 shares. You may be familiar with this stock as it has recently surged after the company's schizophrenia drug got FDA approval.In...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 11 Jun 2009 02:05:29 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/us+market.html"><![CDATA[US Market]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/market+folly.html"><![CDATA[Market Folly]]></category>
		<category domain="http://resources.bnet.com/topic/vanda+pharmaceuticals+inc..html"><![CDATA[Vanda Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VNDA</category>
		<category domain="tickers">VNDA</category>
	</item>
	<item>
		<title><![CDATA[Titan Pharmaceuticals' Story Is Just Beginning]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F139848-titan-pharmaceuticals-story-is-just-beginning%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[VFC submits:  Titan Pharmaceuticals (TTNP.PK) rose another 25%, and may still rise further, after the recent FDA approval of Fanapt. Fanapt, produced by Vanda Pharmaceuticals VNDA to treat schizophrenia, is Titan's licensed product from which it will receive royalty payments of between 8%-10% from net sales of the product....]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 27 May 2009 04:27:14 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/vfc%2527s+stock+house.html"><![CDATA[VFC's Stock House]]></category>
		<category domain="http://resources.bnet.com/topic/vanda+pharmaceuticals+inc..html"><![CDATA[Vanda Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VNDA</category>
		<category domain="tickers">VNDA</category>
	</item>
	<item>
		<title><![CDATA[Vanda Pharmaceuticals: A Biotech Stock Worth Watching]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F139847-vanda-pharmaceuticals-a-biotech-stock-worth-watching%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[VFC submits:  During Tuesday's broad market rally, the action of a few stocks caught my attention and are worth watching for at least the rest of the week.Vanda Pharmaceuticals VNDA: by VFC's Stock House]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 27 May 2009 04:18:28 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/vfc%2527s+stock+house.html"><![CDATA[VFC's Stock House]]></category>
		<category domain="http://resources.bnet.com/topic/vanda+pharmaceuticals+inc..html"><![CDATA[Vanda Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">VNDA</category>
		<category domain="tickers">VNDA</category>
	</item>
</channel>
</rss>
